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nized by C. albicans, C. slabrata appears to emerge 
as the second most prevalent species. 
Supported by NIH/NIDCR DE016466 and MO1 RR06192. 
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Goal: To validate oral vatgancictovir (VGC) in the 
prophylaxis of CMV infection in Lung (Lu) and 
Liver (L) recipients and in the treatment of CMV 
infection/disease in solid organ transplant recipi- 
ents, using pharmacokinetic and pharmacodynamic 
studies in comparison with i/v gancicLovir (GCV). 
Methods: patients undergoing organ transpLanta- 
tion donor or recipient CMV-seropositive receiv- 
ing VGC prophylaxis for a period of 3 months 
(D+/R- Lung recipients, 6 months) were enroLLed. 
Heart (H), Lu, and L recipients received 900mg 
VGC q.d., adjusted to kidney (K) function. No K re- 
cipients received more than 450mg of VGC q.d. 
GCV trough (Ctrough) and peak (Cpeak = 3 hours af- 
ter drug administration) LeveLs, and CMV DNA were 
measured at 7, 30, and 60 days post-transpLant 
(prophyLactic study). Patients who developed CMV 
infection/disease after stopping prophylaxis were 
treated with VGC (1800mg per day adjusted to 
K function and GCV blood LeveLs). GCV trough and 
peak LeveLs, and CMV DNA were measured weekly 
for the first 3 weeks and biweekly thereafter, until 
therapy cessation (therapeutic study). PLasma con- 
centration of GCV is measured by HPLC. 
Results: In the first 8 prophyLaxed patients (6 K, 
and 1 L and 1 H transplant recipient) of 450mg 
VGC q.d., the average GCV concentration was 
0.5±0.3 mg/t at trough, and 3.9±l.0mg/t 3 hours 
after administration. Inter-patient variability was 
substantiaL, especiaLLy for Ctrough (63% of total 
variance), which correlated with the patient's esti- 
mated gtomerutar filtration rate (r square = 42%). 
No CMV DNA was detected during VGC prophy- 
Laxis. Two patients (1 H and 1 L) were treated 
for Late CMV disease. Average GCV Cpeak were 
8.9±2.3 mg/L and 4.6±0.5 rag/L, and GCV Ctrough 
were 2.0±0.9 mg/t and 1.6±0.2 mg/t respectively 
in each patient during induction phase. VGC treat- 
ment afforded a decrease in CMV DNA from 5.2 
and 4.4 Log copies/10E6 cettutes at week 0, to 3.9 
and 3.0 at week 1, and 3.3 and 2.1 at week 3, 
respectively. 
Conclusion: by demonstrating that vatgancictovir 
produces drug LeveLs and viral responses similar 
to i/v gancictovir, this approach is promising as a 
cost effective alternative to randomized controLLed 
studies in validating an oral prodrug in new indica- 
tions. 
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Background: The optimal strategy for prevention 
of CMV disease foLLowing renal transplantation is 
a matter of debate. ProphyLactic treatment may 
result in Late CMV disease, whereas preemptive 
treatment warrants regular consultations with Lab- 
oratory screening. At our center, a preemptive 
strategy is used for high-risk (D+/R-) while foLLow- 
up for intermediate (R+) or Low risk (D-/R-) patients 
is based on cLinicaL symptoms. 
Objectives: The aim of this retrospective analysis 
was to study the occurrence of CMV-antigenemia, 
-viral syndrome and -organ disease in renal trans- 
plant recipients and to correlate their respective 
impact on graft function and Length of hospitaLiza- 
tion, respectively. 
Methods: ALL patients receiving a renal transplant 
from 1/1998 to 12/2003 with a completed foLLow- 
up of 2 years were included. High risk patients 
(D+/R-, group 1) had pp65 surveiLLance tests at 
regular intervals. Antivirat therapy was initiated if 
antigenemia was detected. The outcome of high- 
risk patients was compared with intermediate-risk 
(R+, group 2), and Low-risk (D-/R-, group 3) pa- 
tients. 
Results: A total of 363 patients were eLigibLe, 
69 (19%) were D+/R- (group 1), 230 (63%) were 
D+/R+ or D-/R+ (group 2) and 64 (18%) were D-/R- 
(group 3). The preemptive treatment strategy was 
used in 59 (84%) patients of group 1, 9 (4%) of 
group 2 and 2 (3%) of group 3. ProphyLaxis with gan- 
cictovir (?) was used in 6 (9%) patients of group 1, 
aLL remaining patients were foLLowed cLinicaLLy. 
OveraLL, 70 (20%) patients suffered from at Least 
one CMV episode (antigenemia, viral syndrome, or 
end organ disease). In group 1, 43 (62%) patients 
experienced a CMV episode, 8 (19%) had viremia, 
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25 (58%) a viral syndrome and 10 (23%) organ dis- 
ease. In group 2, 27 (12%) had a CMV episode, 
6 (22%) viremia, 11 (41%) a viral syndrome, and 
10 (37%) organ disease. Group 3 had no docu- 
mented CMV episodes. The average Length of hospi- 
talization for CMV episodes was 11 days in group I, 
and 2.5 days in group 2. At the end of the study 
51 (74%) patients of group I had a functional graft 
(creatinine clearance >30mLlmin), 8 (12%) had 
severely impaired function (C[ <30 mLlmin), 7 (10%) 
were dead, and 3 (4%) had Lost their graft. The 
corresponding numbers for group 2 were 185 (80%), 
28 (12%), 17 (8%), and for group 3 52 (81%), 4 (6%), 
8 (13%), respectively. OveraLL, 25 transplanted pa- 
tients (6.8%) died during the observation period. 
Conclusions: In our experience, a preemptive 
treatment strategy to address the risk of CMV- 
related morbidity foLLowing renal transplantation 
was associated with a markedly higher incidence of 
CMV episodes in the high-risk group as compared to 
the intermediate-risk group. CMV episodes resulted 
in an average hospitalization Length of 11 days and 
a trend towards an increased toss of graft function 
was noted. Therefore and in the Light of the emer- 
gence of newer oral antivira[ agents with a high 
bioavaiLabiLity such as vaLgancicLovir, the current 
strategy has to be reconsidered. 
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Background: Epstein-Barr virus (EBV) meningoen- 
cephatitis is a rare, normaLLy benign, complication 
of infectious mononucleosis. This disease might 
have a more severe outcome in immunosuppressed 
patients. 
Objective: We describe the case of a heart trans- 
plant recipient who died with presumed EBV 
meningoencephatitis. 
Results: A 68 year-oLd man was admitted, 12 years 
after heart transplantation for a cardiomyopathy 
of unknown origin, for dizziness and fatting without 
vertigo or other neuroLogicaL symptoms. 6 years be- 
fore admission he had presented several episodes 
of acute rejection. His immunosuppressive regi- 
men consisted of cyctosporine 75 mg bid and my- 
cophenotate mofeti[ 1250 mg bid. On admission he 
was afebrite and cLinicaL examination was normaL. 
Three days after admission he presented a somno- 
Lence with fever. Cerebrospina[ fluid (CSF) analysis 
revealed Lymphocytic meningitis with 45 [ympho- 
cytes/mm2 and elevated total protein LeveL. An 
EEG was suggestive for associated encephalitis. MRI 
imaging showed no abnormalities except an old is- 
chemic cerebeLLar Lesion. CSF cultures for bacteria 
(incLuding M. tuberculosis) and fungi were nega- 
tive. CSF analysis by PCR was positive for EBV and 
negative for aLL other herpes viruses (HSV-1, HSV-2, 
VZV, CMV, HHV-6), 3C-virus and ToxopLasmosis. EBV 
PCR was also positive on peripheral blood. Im- 
munosuppression was stopped and therapeutic i.v. 
gangicLovir was administered. During the foLLowing 
2 weeks, partial cLinicaL response, EEG improve- 
ment and decrease of EBV copies, both in LCR and 
peripheral blood, were observed. UnfortunateLy 
the cLinicaL condition rapidly degraded thereafter 
and therapeutical retrieval was decided. He died 
secondarily to a bacterial pneumonia. The autopsy 
confirmed the presence of a T-ceLL meningitis but 
no other infectious agents was documented (in- 
cluding rabies and prion disease). At the time of au- 
topsy, no evidence of inflammatory infiltrates, viral 
RNA (LMP) or proteins (EBR) in brain parenchyma 
could be documented. No malignant process could 
be identified. 
Conclusion: Fatal EBV meningoencephaLitis is a 
very rare entity. Despite extensive search for an 
alternative diagnosis to explain the Lymphocytic 
meningoencephaLitis, we could only document a 
concomitant EBV replication, both in the CSF fluid 
and peripheral blood, in this patient. CLinicians 
should be aware of this possible cause of menin- 
goencephaLitis in immunosuppressed patients. 
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Background: In recent years an increasing number 
of cases with BK virus (BKV) associated nephropa- 
thy after renal transplantation were reported from 
several transplant centers. The diagnosis of BKV 
associated nephropathy requires invasive aLLograft 
biopsy sampling; therefore it is not easy to perform 
for aLL patients. Quantitation of BKV DNA Load in 
plasma or urine has a high positive predictive value 
for BKV associated nephropaty. 
